ATE375986T1 - Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten - Google Patents

Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten

Info

Publication number
ATE375986T1
ATE375986T1 AT99940914T AT99940914T ATE375986T1 AT E375986 T1 ATE375986 T1 AT E375986T1 AT 99940914 T AT99940914 T AT 99940914T AT 99940914 T AT99940914 T AT 99940914T AT E375986 T1 ATE375986 T1 AT E375986T1
Authority
AT
Austria
Prior art keywords
particle
forming
preparations containing
containing condensed
forming preparations
Prior art date
Application number
AT99940914T
Other languages
English (en)
Inventor
David Dickason
Piyush Patel
Vincent Corvari
Efraim Shek
Joseph Herman
Jeffry Skell
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26790393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE375986(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE375986T1 publication Critical patent/ATE375986T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT99940914T 1998-08-06 1999-08-06 Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten ATE375986T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9561198P 1998-08-06 1998-08-06
US09/368,409 US6200968B1 (en) 1998-08-06 1999-08-05 Particle-forming compositions containing fused pyrrolocarbazoles

Publications (1)

Publication Number Publication Date
ATE375986T1 true ATE375986T1 (de) 2007-11-15

Family

ID=26790393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940914T ATE375986T1 (de) 1998-08-06 1999-08-06 Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten

Country Status (16)

Country Link
US (2) US6200968B1 (de)
EP (1) EP1102758B1 (de)
JP (1) JP2003524597A (de)
KR (1) KR100616388B1 (de)
CN (1) CN1314900A (de)
AT (1) ATE375986T1 (de)
AU (1) AU756865C (de)
CA (1) CA2338546C (de)
CY (1) CY1107855T1 (de)
DE (1) DE69937351T2 (de)
DK (1) DK1102758T3 (de)
ES (1) ES2296401T3 (de)
MX (1) MXPA01001352A (de)
NZ (1) NZ509596A (de)
PT (1) PT1102758E (de)
WO (1) WO2000008004A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
KR20010083884A (ko) * 1998-10-13 2001-09-03 세파론, 인코포레이티드 눈 질환 치료제
CA2425338C (en) 2000-10-11 2010-04-20 Cephalon, Inc. Compositions comprising modafinil compounds
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
EP1531793A1 (de) * 2002-07-23 2005-05-25 Novartis AG Augensalbenzusammensetzung mit einem arzneimittel, einer salbengrundlage und einem l slichmachenden/dispergierenden mittel
EP2385041B1 (de) 2003-05-01 2013-09-18 Bristol-Myers Squibb Company Pyrazolaminverbindungen, die als Kinasehemmer geeignet sind
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7255687B2 (en) * 2004-11-19 2007-08-14 Percutaneous Systems, Inc. Systems and methods for luminal access
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
CN101365704A (zh) * 2005-12-09 2009-02-11 艾博特公司 来妥替尼晶形1、结晶来妥替尼无水化物和非晶形来妥替尼
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2238973A1 (de) 2009-04-07 2010-10-13 Cephalon France Lyophilisierte Präparate von Proteasominhibitoren
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906108A (en) * 1973-10-12 1975-09-16 Johnson & Johnson Stabilized tretinoin cream emulsion
IE52125B1 (en) * 1980-10-02 1987-06-24 Fox Charles L Jun 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quino-line carboxylic acid and metal salts thereof useful in burn therapy
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH04124123A (ja) * 1990-08-31 1992-04-24 Kao Corp 口腔用組成物
JP2937446B2 (ja) 1990-09-14 1999-08-23 株式会社資生堂 白髪防止黒化剤
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
IE921315A1 (en) 1991-07-03 1993-01-13 Regeneron Pharma Method and assay system for neurothrophin activity
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
AU679752B2 (en) 1993-05-28 1997-07-10 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1996003113A1 (en) * 1994-07-22 1996-02-08 G.D. Searle & Co. Self-emulsifying drug delivery system
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DK0850646T3 (da) * 1996-06-18 2008-05-13 Kyowa Hakko Kogyo Kk Liposompræparater af indolocarbazol-derivater
DK0912184T3 (da) * 1996-06-25 2002-11-25 Cephalon Inc Anvendelse af K-252a-derivat til behandlingen af perifere eller centrale nervelidelser og cytokinoverproduktion
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2338546A1 (en) 2000-02-17
DE69937351D1 (de) 2007-11-29
KR100616388B1 (ko) 2006-08-29
CA2338546C (en) 2010-02-09
MXPA01001352A (es) 2002-04-24
PT1102758E (pt) 2008-01-23
DE69937351T2 (de) 2008-07-17
CY1107855T1 (el) 2013-06-19
EP1102758A1 (de) 2001-05-30
NZ509596A (en) 2004-07-30
AU756865B2 (en) 2003-01-23
US6660729B1 (en) 2003-12-09
CN1314900A (zh) 2001-09-26
AU756865C (en) 2004-02-26
US6200968B1 (en) 2001-03-13
EP1102758A4 (de) 2002-07-24
HK1037622A1 (en) 2002-02-15
EP1102758B1 (de) 2007-10-17
KR20010079618A (ko) 2001-08-22
WO2000008004A8 (en) 2000-06-22
JP2003524597A (ja) 2003-08-19
WO2000008004A1 (en) 2000-02-17
DK1102758T3 (da) 2008-02-04
ES2296401T3 (es) 2008-04-16
AU5467499A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
ATE375986T1 (de) Partikelformende zubereitungen welche kondensierte pyrrolocarbazole enhalten
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
EA199901100A1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
CA2197496A1 (fr) Composition comprenant une dispersion de particules de polymeres dans un milieu non aqueux
ATE284677T1 (de) Herstellung von pulveragglomeraten
AU2597500A (en) Method of forming meltblown webs containing particles
ID27586A (id) Komposisi aerosol
NO20013994D0 (no) Fremgangsmate for fremstilling av tert-butyl (E)-(6[2-[4-(4- fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2,2-dimetyl[1,3]dioksan-4-yl)acetat
NO996484D0 (no) Ny fremgangsmåte for fremstilling av paroxetin faststoffdispersjon
EA199700281A1 (ru) Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц
NO992780L (no) Forbedrede farmas°ytiske preparater
DE69939555D1 (de) Granuliertes Brotverbesserungmittel zur Herstellung von Teigwaren
ES2196743T3 (es) Sorbitol en polvo y su procedimiento de preparacion.
BR9909357A (pt) Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
MXPA99004399A (es) Procedimiento para la fabricacion de substancias heterogeneas en polvo.
BR9810633A (pt) Composições de detergente lìquido não aquoso contendo partìculas enzimáticas tendo densidade reduzida
NO20062381L (no) Partikkeldannende sammensetninger inneholdende kondenserte pyrrolokarbazoler
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
EA200200294A1 (ru) Сферические агломераты телитромицина, способ их получения и их применение для приготовления лекарственных форм
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA200101106A1 (ru) Фармацевтический комплекс
EA200200486A1 (ru) Пероральный раствор, содержащий галантамин и подсластитель
DK0662835T3 (da) Nye farmaceutiske præparater af spiramycin
EA200100107A1 (ru) Новые 2,3,3a,4,9,9a-гексагидро-8-гидрокси-1h-бенз[f]индолы, способ их получения и их применение в качестве лекарственных средств

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1102758

Country of ref document: EP